Monthly Oral PrEP Candidate MK-8527 Shows Promise in Phase 2 Study
A new once-monthly oral HIV prevention drug, MK-8527, has shown a favorable safety profile and promising pharmacokinetics, according to interim results from a phase 2 study presented on July 14 at the IAS 2025 conference in Kigali (Abstract 6515). In the randomized, double-blind, multicenter trial involving 350 participants—over half of them women—MK-8527 was well tolerated…
